Want to see JP:4521 full AI Analyst Report?
Top Page
Kaken Pharmaceutical Co
(4521)
Select Model
Select Model
Rating:63Neutral
Price Target:
¥4,276.00
▲(7.17% Upside)
Action:Reiterated
Date:08/17/26
The score is held back primarily by weakened recent financial performance and negative operating/free cash flow, partially offset by a very conservative balance sheet. Technical indicators show positive momentum, and valuation is supported by a moderate P/E and strong dividend yield.
Positive Factors
Conservative Balance Sheet
Very low leverage and a large equity base reduce refinancing risk and provide flexibility to sustain R&D, support commercialization, or absorb periods of weaker earnings without balance-sheet strain.
Negative Factors
Sharp Revenue Contraction
The substantial revenue decline indicates pressure on product demand, lifecycle performance, or market conditions. Sustained contraction would weaken operating leverage and reduce the resources available for future pharmaceutical development.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and a large equity base reduce refinancing risk and provide flexibility to sustain R&D, support commercialization, or absorb periods of weaker earnings without balance-sheet strain.
Read all positive factors
Kaken Pharmaceutical Co (4521) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥143.35B
Dividend Yield4.77%
Average Volume (3M)114.17K
Price to Earnings (P/E)14.6
Beta (1Y)0.27
Revenue Growth-6.86%
EPS Growth-17.71%
CountryJP
Employees1,114
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)333.12
Shares Outstanding44,139,730
10 Day Avg. Volume95,330
30 Day Avg. Volume114,170
Financial Highlights & Ratios
PEG Ratio-0.87
Price to Book (P/B)1.06
Price to Sales (P/S)2.04
P/FCF Ratio-11.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)123.1
Revenue Forecast (FY)¥83.17B
Kaken Pharmaceutical Co Business Overview & Revenue Model
Company Description
Kaken Pharmaceutical Co., Ltd. is involved in the development, manufacturing, and commercialization of a diverse range of medical goods, health devices, and agricultural chemicals, serving both domestic and global markets. Their extensive product ...
How the Company Makes Money
Kaken Pharmaceutical primarily makes money by selling prescription pharmaceuticals in Japan. Its core revenue model is to (1) develop or in-license drug candidates, (2) obtain regulatory approvals, and (3) commercialize approved products as brande...
Kaken Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
86
Very Positive
Cash Flow
32
Negative
| Breakdown | TTM | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 94.65B | 76.87B | 94.03B | 72.04B | 72.98B | 76.03B |
| Gross Profit | 58.08B | 39.24B | 58.26B | 38.54B | 39.56B | 41.58B |
| EBITDA | 20.34B | 5.68B | 22.02B | 12.57B | 9.40B | 16.38B |
| Net Income | 12.46B | 2.14B | 13.95B | 8.03B | 5.44B | 9.55B |
Balance Sheet | ||||||
| Total Assets | 176.34B | 178.22B | 190.42B | 171.62B | 166.33B | 165.18B |
| Cash, Cash Equivalents and Short-Term Investments | 55.40B | 50.70B | 70.08B | 65.32B | 74.26B | 74.62B |
| Total Debt | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B | 3.85B |
| Total Liabilities | 28.89B | 30.59B | 37.78B | 27.87B | 29.49B | 26.85B |
| Stockholders Equity | 147.45B | 147.62B | 152.63B | 143.75B | 136.26B | 137.75B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -14.07B | 25.64B | 716.00M | 7.27B | 10.35B |
| Operating Cash Flow | 0.00 | -11.08B | 29.78B | 2.58B | 9.25B | 13.34B |
| Investing Cash Flow | 0.00 | 315.00M | -19.65B | -5.85B | -2.63B | -7.89B |
| Financing Cash Flow | 0.00 | -8.84B | -5.37B | -5.66B | -6.99B | -8.13B |
Kaken Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | ¥112.29B | 12.73 | 6.64% | 2.42% | 14.72% | 52.55% | |
64 Neutral | ¥163.59B | 11.87 | 6.31% | 2.81% | 10.35% | 16.60% | |
63 Neutral | ¥143.35B | 14.62 | 6.94% | 4.77% | -6.86% | -17.71% | |
60 Neutral | ¥182.59B | 22.09 | 4.53% | 2.16% | 6.78% | -48.34% | |
52 Neutral | ¥59.38B | 29.84 | ― | 5.05% | -4.71% | -78.91% | |
52 Neutral | ¥163.36B | 21.74 | ― | 3.36% | 11.08% | 701.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:4521
Kaken Pharmaceutical Co
3,980.00
312.41
8.52%
JP:4547
Kissei Pharmaceutical Co
4,005.00
-302.46
-7.02%
JP:4553
Towa Pharmaceutical Co
3,710.00
806.47
27.78%
JP:4534
Mochida Pharmaceutical Co., Ltd.
3,300.00
133.97
4.23%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,128.00
-335.21
-22.91%
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,639.00
-317.83
-16.24%
Kaken Pharmaceutical Co Corporate Events
Kaken Pharmaceutical Swings to Strong Profit but Suspends Dividend Despite Sales Surge
Aug 7, 2026
Kaken Pharmaceutical reported strong top-line growth for the three months ended June 30, 2026, with net sales climbing 59.8% year on year to ¥30.15 billion and profit attributable to owners of the parent surging to ¥8.44 billion, boostin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.